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The small multidrug resistance (SMR) protein family is a bacterial multidrug transporter family. As suggested by their title, SMR proteins are
composed of four transmembrane α-helices of approximately 100–140 amino acids in length. Since their designation as a family, many
homologues have been identified and characterized both structurally and functionally. In this review the topology, structure, drug resistance, drug
binding, and transport mechanisms of the entire SMR protein family are examined. Additionally, updated bioinformatic analysis of predicted and
characterized SMR protein family members was also conducted. Based on SMR sequence alignments and phylogenetic analysis of current
members, we propose that this small multidrug resistance transporter family should be expanded into three subclasses: (i) the small multidrug
pumps (SMP), (ii) suppressor of groEL mutation proteins (SUG), and a third group (iii) paired small multidrug resistance proteins (PSMR). The
roles of these three SMR subclasses are examined, and the well-characterized members, such as Escherichia coli EmrE and SugE, are described in
terms of their function and structural organization.
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This review marks the 12-year anniversary of the small
multidrug resistance (SMR) proteins since their description as a
family [1]. As their name implies, these small (∼12 kDa)
integral inner membrane proteins range from 100 to 140 amino
acids in length [1,2] and confer resistance to a variety of qua-
ternary ammonium compounds (QAC) in addition to other
lipophilic cations. These proteins are believed to span the cy-
toplasmic membrane as four transmembrane (TM) α-helices [1]
with short hydrophilic loops making them very hydrophobic, a
characteristic that permits their solubilization in organic solvents
[3–6]. The SMR protein family is one of five protein families
that comprise the drug/metabolite transporter (DMT) superfam-
ily [2,7–9]. Based on these characteristics, members of the SMR
protein family are distinct from the other four transporter fami-
lies, namely the major facilitator superfamily (MFS) (as re-
viewed by [10]), the ATP-binding cassette family (ABC) (as
reviewed by [11–13]), multiple antimicrobial extrusion family
(MATE) (reviewed by [9,14]) and the resistance/nodulation/cell
division family (RND) (reviewed by [15,16]). The remaining
multidrug transporter protein superfamilies are composed of
5–14 TM strands and catalyze the transport of a wide variety
of substrates such as sugars, peptides, complex carbohydrates,
drugs, and metals in various ionic states driven by proton motive
force (PMF) or ATP-dependant mechanisms [9]. Unlike other
multidrug transporter proteins, the SMR protein family has only
demonstrated transport of lipophilic compounds, primarily QAC
as well as a variety of antibiotics [17], commonly used antisep-
tics, and detergents (for examples, see [18–20]). Similar to MFS
superfamily proteins, SMR proteins also demonstrate drug ef-
flux via an electrochemical proton gradient [3,18,21,22]. As
such, SMR proteins also have been classified as proton-depen-
dent multidrug efflux systems [23].
Drug efflux has not been demonstrated for all identified
SMR proteins and this characteristic resulted in the divergence
of this family into two classes: small multidrug pumps (SMP)
and suppressor of groEL mutation proteins (SUG). This classi-
fication is based on their conferred phenotype [24] and was
supported with their phylogenic assignment into two major
branches [1,2,9,25].
Since the SMP and SUG subclass protein designations, an-
other distinct group of SMR homologues have been identified
and characterized for their multidrug resistance and substrate
transport activity. These SMR homologues are unique from
either subclass as they require co-expression of two separate
SMR genes within the host bacterium to confer the same
resistance properties as other isogenic SMP and SUG members
[2]. Characterized members of this paired SMR (PSMR) protein
group include Escherichia coli YdgE and YdgF [26], Bacillus
subtilis EbrA and EbrB, [27] YkkC and YkkD, YvaD and YvaE,
YvdR and YvdS [20].
SMR protein family members from each subclass have been
identified on a variety of plasmids and transposable elements that
endow high levels of resistance to awide range of antibiotics such
as β-lactams [28–30], cephalosporins [31,32], dihydrofolate
inhibitors [33], as well as other aminoglycosides [34–36]. Thefrequency of their occurrence with other drug resistance genes
strongly suggests that there is a tight genetic linkage between
both antibiotic and SMR resistance genes [28,29]. The co-selec-
tion of antibiotic and antiseptic resistance genes correlates with
the increased usage of both antiseptics and antibiotics in clinical
environments [19,28,29,37,38]. This rapid horizontal spread of
SMR homologues makes them a critical protein to characterize
and an important candidate for transport mechanism studies.
Here we review current information pertaining to the multi-
drug resistance, transport mechanisms, and structural arrange-
ments of members from the entire SMR protein family, an
examination not performed since the review in 1996 [1]. Our goal
was to summarize current information for all known SMR
homologues in addition to updating the SMR protein family by
performing bioinformatic analyses. Taken from these analyses,
which consist of SMR protein alignments and phylogenetic trees,
we propose that this family is composed of three subclasses:
SMP, SUG and PSMRs. The following sections will discuss each
of the three subclasses of the SMR protein family, summarize
differences in their conferred resistance phenotypes, emphasize
the diversity and conservation of their primary sequences, and
explore their architecture and transport activity. Hence, the clas-
sification nomenclature used above will be applied throughout
the remaining discussion of the SMR protein family members.
2. SMR family diversity
There are over 250 annotated SMR protein sequences in the
(NCBI) protein database. Protein database searches of both
(TIGR) and NCBI databases (performed as of December 2006)
using E. coli EmrE (Eco-EmrE) as a seed sequence reveal that
52% of completely sequenced bacterial genomes possess SMR
homologues. Interestingly, this estimate remains in agreement
with previous SMR protein bioinformatic surveys performed in
2000 and 2001 [2,34]. Overall, both Gram-negative and Gram-
positive bacteria have two SMR homologues per species. How-
ever, many species from bacilli and γ-proteobacteria classes can
possess 3–8 homologues.Within the kingdomArchaea, only 31%
of completed genomes identified SMR homologues all of which
belong to the sub-phylumEuryarchaeota. Thus far, only one SMR
homologue is present on the chromosomes of the surveyed
Archaeabacteria. This suggests that SMR gene duplication events
have resulted in their current bacterial diversity [9,39].
Since far more SMR homologues have been identified on
chromosomes, plasmids, and integrons from the initial protein
family review [1], it suggests that members of this transporter
family have greater structural and functional diversity than was
initially assumed. Previous phylogenetic characterization of the
SMRprotein family revealed two subclasses: the small multidrug
pumps (SMP) and suppressor of groELmutation proteins (SUG)
[1]. Genome sequencing initiatives have enabled the identi-
fication of another group of SMR family proteins: paired SMR
proteins (PSMR). Members of the PSMR group are distinct from
either the SMP or SUG group since they are believed to function
within the membrane as heterologous pairs of SMR proteins
[25,9,2]. Our current phylogenetic tree of 101 annotated SMR
protein sequences representing members from each SMR
1816 D.C. Bay et al. / Biochimica et Biophysica Acta 1778 (2008) 1814–1838subclass serves to highlight these differences (Fig. 1). Hence, we
propose that the SMR protein family is composed of three
subclasses, specifically SMP, SUG, and PSMR. Therefore, the
remaining discussionwill summarize the differences in conferred
resistance phenotypes, emphasize the diversity and conservation
of their primary sequences, and explore their architecture and
transport activity relative to each SMR subclass.
3. The small multidrug protein subclass
SMP subclass proteins within the SMR family were grouped
together on the basis of their functional and structural similarity
in addition to their phylogenetic distribution [1,2,7,25,39].
This class of proteins are primarily characterized by theirFig. 1. A phylogenetic tree of the SMR protein family. The unrooted phylogenetic
The Archaeal Archaeoglobus QacE sequence served as the outgroup for this tree
their respectively numbered branch due to tight clustering within the branches of
values from 65–70% (squares), 70–79% (circles), 80–89% (stars), and 90–100
encoded SMR proteins are underlined and E. coli SMR homologues are listed
(black) subclasses are indicated on the tree according to their respective colours
(see Supplementary Fig. 1).ability to confer multidrug resistance to Gram-negative (EmrE
from E. coli) and Gram-positive (Smr from Staphylococcus
aureus) bacteria as well as Archaea (Hsmr from Halobacter-
ium salinarum) from the expression of a single gene [1,2,7].
Originally, members of the SMP class consisted of the plasmid
encoded S. aureus Smr (Sau-Smr) [22,40–43], the chromo-
somally encoded Eco-EmrE [44–46], and integron encoded
Klebsiella QacE and QacEΔ1 [21]. This class has expanded
significantly to include plasmid and integron encoded QacF,
QacG, QacH, and QacJ proteins [17,30,38,47–59] and other
chromosomally encoded SMR homologues based on their pre-
dicted sequence similarities and from their functional, structural,
and phylogenetic groupings with other SMP proteins (see sum-
mary in Table 1).tree is based on Neighbour Joining analysis of 101 SMR protein sequences.
. In some cases, SMP and PSMR sequences are numbered and listed around
this tree. One thousand bootstrap replicates were performed and confidence
% (asterisks) are listed beside their respective nodes. Plasmid and integron
in bold. Branches corresponding to PSMR (blue), SUG (green), and SMP
. SMR sequence accession numbers are indicated in the sequence alignment
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as methyl viologen resistance protein C, MvrC and ethidium
bromide resistance protein, Ebr) is currently championed as the
structural archetype of all SMR proteins (as reviewed by [60];
Fig. 2A). This protein has been characterized extensively using
numerous biophysical and high-resolution techniques such
as X-ray diffraction and cryo-electron microscopy (cryo-EM)
[60–67]. In addition to Eco-EmrE, other characterized proteo-
bacterial SMP proteins include Pseudomonas aeruginosa Pau-
EmrE (γ-proteobacteria) [26,35] and Bordetella pertussis Bpe-
EmrE (β-proteobacteria) [26] (Table 1). Upon comparison,
EmrE homologues Pau-EmrE and Bpe-EmrE share 45% and
50% identity with Eco-EmrE respectively and are fairly con-
sistent in protein length (107–110 amino acids). Based on their
overall sequence identity to Eco-EmrE, structurally and func-
tionally uncharacterized SMR homologues have also been iden-
tified on chromosomes of other representative proteobacteria.
For example, Neisseria meningitidis Nme-EmrE (42%; α-pro-
teobacteria), Myxococcus xanthus Mxa-EmrE (54%; δ-proteo-
bacteria), and Campylobacter jejuni Cje-EmrE (27%; ε-
proteobacteria) are expected to share similar transport activities
as Eco-EmrE.
Among Gram-positive bacteria S. aureus multidrug resis-
tance protein Sau-Smr (also referred to as Ebr, QacC/D) was
one of the first proteins identified and characterized within the
SMR family (Table 1). Like Eco-EmrE, Sau-Smr has also been
functionally and structurally characterized using a combination
of genetic and biophysical techniques [22,68]. SMP homo-
logues within Gram-positive bacteria have been identified on
chromosomes [2,9,25] as well as on a variety of multi-
resistance plasmids from clinical isolates [18,36,69–74] of both
Gram-positive and Gram-negative bacteria. Besides Sau-Smr,
only one actinobacterial SMP class protein, Mycobacterium
tuberculosis Mtu-Smr, has been functionally characterized and
demonstrated drug resistance and transport activities similar to
Sau-Smr [26,75]. Mtu-Smr shares moderate sequence identity
(32%) to Sau-Smr but both proteins share greater sequence
identities when compared to Eco-EmrE (41% and 38% re-
spectively). Uncharacterized SMP homologues have been
identified among other Gram-positive bacteria. One such
protein is Chlorobium ferrooxidans Cfe-Smr (44%; chlorobia)
identified by its high degree of sequence identity to Sau-Smr.
This protein likely shares similar drug efflux abilities as Sau-
Smr and Mtu-Mmr.
Only one SMR homologue within Archaeabacteria, Halo-
bacterium salinarium (Hsmr), has been functionally and structur-
ally characterized [76,77]. Similar to its Eubacterial counterparts
Eco-EmrE and Sau-Smr (41% and 39% sequence identity to Eco-
EmrE and Sau-Smr), Hsmr has similar substrate transport pro-
perties and signature sequence elements [76]. Hsmr has been
characterized more recently based on its high content of A and V
residues (40%), a feature that makes it an excellent candidate for
structural conservation and site-directed mutagenesis studies
(Table 1). Besides Hsmr, other Archaebacterial SMR homo-
logues have been identified from genome database surveys such
as Methanosarcina acetivorans Mac-Smr (also referred to as
EbrA) and Haloarcula marismortui Hma-Smr (annotated asQacE). Both SMR homologues share 39% and 40% identities to
Eco-EmrE respectively [2,9,25,39,78].
Remaining SMP members, QacE, QacEΔ1, QacF, QacG,
QacH, and QacJ, have been detected on plasmids and/or on
transposable elements (integrons) from a variety of antibiotic-
resistant bacteria (Table 1). This nomenclature is based on their
conferred phenotype to quaternary ammonium compounds and
permits their distinction from the chromosomally encoded SMP
proteins. In general, all of these SMR homologues are fairly
consistent to Eco-EmrE and Sau-Smr due to similar protein
length (107–110 amino acids) drug resistance phenotypes. The
SMP protein QacE was originally identified on the 3′ conserved
segment of the Class 1 integron carried by the plasmid pR751
from Klebsiella aerogenes and conferred QAC transport acti-
vity to its host [21]. The semi-functional QacEΔ1, which is
identical in sequence to QacE but lacks the last 16 amino acids
from the C-terminus, was also encoded on this integron [21].
Since then, numerous Class 1 integrons carrying QacE and/or
QacEΔ1 have been identified from both Gram-negative and
Gram-positive bacteria and their presence is often correlated
with bacteria pre-exposed to QACs [21,33,38,47,48,51–53,55,
58,79–81]. Besides its frequent association with QacE, QacEΔ1
has also been found on integrons that encode another SMP
protein, QacF [30,47,59] (Table 1). QacF shares high sequence
identity to QacE (68%) and has been detected on the Class 1
integron located on the IncP-1β plasmid pB8 as well as on
plasmid pR751 [47,59,82,83].
QacG has been frequently isolated from QAC-resistant plas-
mids from staphylococci in the food industry as well as from the
staphylococci plasmid pST94. QacG shares 69% sequence
similarity to Sau-Smr [17,50,54,57]. The SMR protein, QacH,
has been detected on the staphylococcal plasmid p2H6 and
shares 78% identity to Sau-Smr [49]. Finally, QacJ, another
plasmid-encoded staphylococcal resistance protein has also
been identified on the QAC resistance plasmid pNVH01, a new
member of the pC194 family of rolling circle replication plas-
mids [56] (Table 1). Like other previously identified Staphylo-
coccus sp. SMR proteins, QacJ shares high sequence identities
to known proteins of the small multidrug resistance family: Sau-
Smr (73%), QacG (83%), and QacH (73%) (Table 1).
4. The suppressor of groEL protein subclass
The second class of proteins within the SMR protein family
are referred to as suppressor of groELmutation protein (SUG or
SugE) based on their conferred phenotype [1,24] and phylogenic
assignment [2,9,25] (Fig. 1). The chaperonin GroEL (homo-
loguous to the eukaryotic heat shock protein Hsp60) is part of the
GroEL/GroES chaperone complex that assists with the proper
folding of proteins within bacteria (as reviewed by [84–86]).
Like SMP proteins, SUG proteins have demonstrated isogenic
transport activity but SUG proteins lack the capability to recog-
nize or transport the diverse QAC and lipophilic dyes demon-
strated by SMP proteins [87,88]. SUG proteins have also been
shown to import [88] and export [87] a very narrow range of
these substrates in over-accumulation studies. Little is known
about the nature of the SUG protein relationship to GroEL and
Table 1
Previously identified SMR family members
SMR proteins Designation Organism Location Amino
acid
length
NCBI
accession
number
Reference
SMP proteins
SmrEbr/
QacC/Qac a
Staphylococcus or small
multidrug resistance protein/
ethidium bromide resistance
protein/quaternary ammonium
compound resistance
protein C or D
Staphylococcus aureus Chromosome 107 AAM94143 [19,22,37,41–43]
Staphylococcus aureus,
Staphylococcus epidermidis,
Staphylococcus pasteuri,
Staphylococcus warneri,
Stenotrophomonas maltophilia
Plasmids: pR751, pSK41,
pSK108, pTZ22, pSP187,
pT181, pTS827, pPI-1,
pPI-2, pSW174, pSW49,
pSepCH, pST187, pNVH99
107 NP_863640 [18,19,29,36,
69–74,158,159,
163,165,166]
Smr-2 a Small multidrug resistance
protein 2
Staphylococcus aureus,
Psuedomonas aeruginosa
Class 1 integrons:
In111, In120
105 CAH04647 [30,160,161,167]
EmrE/MvrC/
Ebr a
Ethidium multidrug resistance
protein E/methyl viologen
resistance protein C
Escherichia coli Chromosome 110 P23895 [3,44,45]
QacE a Quaternary ammonium
compound resistance protein E
Klebsiella aerogenes,
Enterobacter aerogenes
Plasmid: pR751 Class 1
Integron: In53, Tn5090
110 P0AGD0 [21,31,48,51,52,
79,155]
QacEΔ1 a Semi-functional derivative of
quaternary ammonium
compound resistance protein E
Klebsiella pneumoniae,
Escherichia coli, Salmonella
enterica, Morganella morganii,
Pseudomonas aerogenes
Plasmids: pR751, pLMO20,
R388, pDGO100, pB8
Class 1 Integrons: In53, In7,
In111, In116, In121
115 ABF48386 [21,31,48,51,52,
79,162]
QacF a Quaternary ammonium
compound resistance protein F
Enterobacter aerogenes,
Vibrio cholerae,
Achromobacter denitrificans
Plasmid: pB8, p3iANG
Class 1 Integrons: Tn5501
110 Q9X2N9 [47,59,168]
QacGa Quaternary ammonium
compound resistance protein G
Staphylococcus saprophyticus,
Aeromonas salmonicida
Plasmid: pST94 Class 1
Integrons: InC
107 O87866 [17,54,57]
QacHa Quaternary ammonium
compound resistance protein H
Staphylococcus saprophyticus,
Escherichia coli,
Bordetella avium
Plasmids: p2H6 Class 1
Integrons
Ssa 107
Eco 110
Bav 109
O87868,
AAX56371,
CAJ50309
[49,164,169,170]
QacJ a Quaternary ammonium
compound resistance protein J
Staphylococcus simulans,
Staphylococcus intermedius
Staphylococcus aureus
Plasmid: pNVH01 107 CAD55144 [56,57]
Pae-EmrE/
Pasmr a
Pseudomonas aeruginosa EmrE
homologue/Pseudomonas
aeruginosa (PA) small
multidrug resistance protein
Pseudomonas aeruginosa Chromosome 110 PA4990 [26,35]
Mtu-Smr/
TBsmr/
Mmr a
Mycobacterium tuberculosis
(TB) SMR homologue/
Mycobacterium smegmatis
multidrug resistance homologue
Mycobacterium tuberculosis,
Mycobacterium smegmatis
Chromosome 107 P95094 [26,75]
Bpe-EmrE/
BPsmr a
Bordetella pertussis EmrE
homologue/Bordetella pertussis
(BP) SMR homologue
Bordetella pertussis Chromosome 111 b
109
CAJ50309 [26]
Hsmr/EbrB a Halobacterium small
multidrug resistance protein
Halobacterium salinarum Chromosome 112 NP_444228
OE3652F c
[76,77]
PSMR proteins
YdgE/Em109/
MdtI/
b1599 a
SMR homologues YdgE of
YdgEF complex/Escherichia
coli membrane protein 109/
multidrug transporter I
Escherichia coli Chromosome YdgE 109 YP_540797
P77670
[26,98,99,102,171]
YdgF/Em121/
MdtJ/
b1600 a
SMR homologue YdgF of
YdgEF complex/Escherichia
coli membrane protein 121/
multidrug transporter J
Escherichia coli Chromosome YdgF 121 NP_416117
P77412
[26,98,102,171]
EbrAB a Ethidium bromide resistance
proteins A and B
Bacillus subtilis Chromosome EbrA 105
EbrB 117
O31792
O31791
[20,27,97,134,135]
YkkCDa Multidrug resistance proteins
YkkC and YkkD
Bacillus subtilis Chromosome YkkC 112
YkkD 105
Q65KV1
Q65KV0
[20]
YvaDE Multidrug resistance proteins
YvaD and YvaE
Bacillus subtilis Chromosome YvaD 133
YvaE 119
CAB15361
CAB15362
[2]
YvdRS Multidrug resistance proteins
YvdR and YvdS
Bacillus subtilis Chromosome YvdR 106
YvdS 111
CAB15455
CAB15454
[2]
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SugES a Suppressor of GroEL
mutation protein
Escherichia coli Chromosome 105 AAC46 4 5 3
P69937
[24,87,172]
SugE SugES homologue;
sequence identical to
Citrobacter freundii
Escherichia coli,
Salmonella sp., Shigella sp.,
Klebsiella oxytoca
Plasmid: p541, pTHK11
transposable element: bla
(CYM-2)-carrying element
105 AAQ16658 [32,92,93,95,96]
SugE SugES homologue Proteus vulgaris Chromosome 104 P20928 [91]
SugE a SugES homologue Citrobacter freundii Chromosome 105 AAC46457 [88,172]
SugE1 and
SugE2
SugES homologue
proteins 1 and 2
Deinococcus radiodurans Chromosome SugE1 113
SugE2 103
AAF10580
AAF10579
[2]
SocA2/SocX frdD homologue;
SugE homologue
Myxococcus xanthus Chromosome 105 Q7M0S1 [1,173]
a Indicates SMR proteins that have demonstrated drug resistance.
b Protein sequence obtained from reference.
c Accession number corresponds to entry from Halobacterium salinarum genome sequencing project (www.halolex.mpg.de).
Table 1 (continued)
SMR proteins Designation Organism Location Amino
acid
length
NCBI
accession
number
Reference
SUG proteins
1819D.C. Bay et al. / Biochimica et Biophysica Acta 1778 (2008) 1814–1838the protein itself has been speculated to possess some chaperone
activity [1,2,9,25,87]. However, over-accumulation of SUG
protein has been confirmed to suppress GroEL mutations (R.J.
Turner, unpublished results). Taken together with their potential
import activity this suggests that these proteins may play an
important role in the uptake of chaperone regulatory com-
pounds. In general, SUG proteins are similar in length and share
the same predicted four α-helix TM strand composition as SMP
proteins [89,90] (Fig. 2B). The genes that encode for SUG
proteins are also located at a locus separate from other SMR
homologues emphasizing their distinct activity from other SMR
proteins [2,91].
Like other SMP genes, SUG encoding genes have been
identified on plasmids, specifically the Klebsiella β-lactam
resistance plasmid pTKH11 [32,92–95], and on Class 1 inte-
grons isolated from various Enterobacteriaceae [96] (Table 1).
Interestingly, almost all sugE genes identified from plasmids
and transposons are genetically identical to the sugE gene of
Citrobacter freundii [95] perhaps due to the high proliferation
of its parent vector or due to the enhanced expression fidelity of
the C. freundii sugE gene itself [88] (Fig. 2B). It is uncertain
what advantage these SUG genes confer to the host organism
since E. coli SugE (Eco-SugE) protein demonstrates transport
of only a very narrow subset of QAC and cationic dyes [87].
Eco-SugE was the first SUG member that was identified
from suppressor screens of E. coli harbouring mutations in the
chaperone gene groEL [24]. Thus far, only a single copy of
sugE gene is present in bacterial chromosomes with the excep-
tion of Deinococcus radiodurans, which has a pair of sugE
genes (sugE1 and sugE2) located on chromosome 1 [2].
5. PSMR subclass proteins: paired SMR proteins
PSMR proteins are distinct from SMP and SUG subclass
proteins due to the requirement for both copies of each SMR
homologue to be simultaneously expressed in order to confer a
drug resistance phenotype [2,20,97,98]. PSMR homologues
were initially identified from genome database surveys [2,9]and have since been characterized using genetic and biochem-
ical techniques [20,27,97–104]. PSMR protein pairs generally
consist of one protein with typical SMR protein length and a
remaining protein that is longer (for example, YdgF has 121 aa;
YdgE has 109 aa; Table 1; Fig. 2C, D). PSMR proteins are
structurally unique from other SMR homologues due to the
presence of longer hydrophilic loops as well as an extended
hydrophilic C-terminus in one of the two PSMR protein pairs
(Fig. 2C, D). Like their group name implies, genes encoding for
these PSMR proteins are located in pairs or at most 2 genes
apart on the host chromosome at distinct loci, separate from
SMP and SUG homologues [2,98]. The number of PSMR
protein pairs among bacteria can vary depending on the orga-
nism, ranging from a single pair in E. coli to 3 or more pairs in
B. subtilis [2,9,98].
Experimental characterization of PSMR homologues among
Gram-negative bacteria has focused primarily on E. coli PSMR
homologues YdgE and YdgF (formerly referred to as Em109
and Em121 or MdtI and MdtJ respectively) [26], [98–104]
(Table 1 and Fig. 2C, D). Based on these studies, only the co-
expression of the cloned ydgE and ydgF gene pair (YdgEF) in a
drug-sensitive E. coli strain conferred host resistance to QACs
[98]. Each protein, YdgE and YdgF, shares 31% and 30%
identity respectively to Eco-EmrE and low sequence identity
(31%) to each other making the pair highly distinct. PSMR
proteins also have been identified in Pseudomonas and Shigella
species and TIGR and NCBI Blast searches of current proteo-
bacterial genome databases using Eco-EmrE and Eco-YdgEF as
seed sequences suggest that many other potential PSMR
sequences exist.
In the Gram-positive bacterium, B. subtilis, SMR homo-
logues have been identified at four distinct loci where each pair
encodes for PSMR protein pairs EbrA and EbrB (EbrAB),
YkkC and YkkD (YkkCD), YvdR and YvdS (YvdRS), and
YvaD and YvaE (YvaDE) [2,9,20] (Table 1). Among these pairs,
only EbrAB and YkkCD have conferred host drug resistance
upon simultaneous co-expression [20,97]. PSMR protein pairs
demonstrate moderate to low sequence identity to Sau-Smr,
Fig. 2. Small multidrug resistance protein topology diagrams. The topology of bacterial E. coli EmrE (panel A) and C. freundii SugE (panel B), and the PSMR
protein pair in E. coli YdgE (panel C) and YdgF (panel D) are displayed. The residues of each protein are shown in circles. Both leaflets of the phospholipid
bilayer in panels A–D are represented by two horizontal lines that indicate potential periplasmic and cytoplasmic domains. Grey rounded rectangles behind
circled residues show predicted TM α-helices. Amino acids are listed according to single letter code and those listed in red indicate residues that demonstrated
altered drug resistance profiles or capable of chemical cross-linking when targeted by site-directed mutagenesis. Shaded circles behind the residues show
the conserved motif (blue) for all SMR proteins as well as conserved residues that are specific to SMP (green), SUG (yellow), and PSMR (violet) subclasses in
each panel.
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(29%) and to each other within each EbrAB or YkkCD pair
(45% and 26%), respectively. PSMR homologues of both these
pairs have been identified among other Bacillus species and
individual PSMR pairs have been identified in other Gram-
positive bacteria such as the EbrAB/NepAB pair on the pAO1
plasmid from Arthrobacter nicotinovorans [105,106].
In contrast to B. subtilis EbrAB and YkkCD pairs, only YvaE
of the YvaDE pair has demonstrated a drug resistance phenotype.
Furthermore, neither protein in the YvdRS pair conferred a drug
resistance phenotypewhen expressed as single genes or in tandem
[2].When compared to Sau-Smr, individual proteins YvaD (14%)
and YvdS (17%) have far lower sequence similarities than their
respective pairs YvaE (41%) and YvdR (35%), perhaps reflecting
their functional divergence from other PSMR pairs. Based on its
drug-susceptible phenotype when expressed alone, both YvaD
and YvdRS have been suggested to play a role as a chaperone,
similar to SUG proteins [2,9]. According to their phylogenetic
distribution, both of these proteins groupwithin the SUG subclass
lending support for transport activity similar to the SUG subclass
[2] (Fig. 1). However, experimental data supporting their ability to
suppress a groEL phenotype has not been explored and would
benefit from further analysis.
6. SMR protein phylogenetic distribution
To compare the functional groupings of SMR homologues
identified among Bacteria and Archaeabacteria, an alignment
of 101 protein sequences was performed using the program
ClustalW [107,108]. This alignment was used to create an up-
dated phylogenetic tree using the Neighbour Joining (NJ)
program ‘neighbour’ [109] and parsimony program PROTPARS
[110] available online (http://bioweb.pasteur.fr/seqanal/phylog-
eny/phylip-uk.html). SMR protein trees obtained from both
methods showed similar branching patterns and confidence
values, therefore the NJ tree has been chosen for further
discussion (Fig. 1).
In agreement with previous phylogenetic analyses, the current
SMR protein family tree still demonstrates two major protein
branches (Fig. 1) [1,2,9,39]. The major branch is composed of
previously identified SMP proteins such as Sau-Smr and Eco-
EmrE which cluster together with the other plasmid encoded
members QacE, QacEΔ1, QacF, QacH, QacJ. Other predicted
SMP proteins such as Neisseria Nme-EmrE and Chlorobium
Cfe-Smr also group within this branch validating their classi-
fication within the SMP subclass.
The remaining branch is composed primarily of SUG pro-
teins (Fig. 1). Experimentally characterized SUG proteins, Eco-
SugE and Cfr-SugE, show homology to other predicted SUG
homologue sequences from Gram-negative and Gram-positive
bacteria and Archaea supporting their SUG designation. This
branch also indicates that five predicted SMR homologues
annotated as SMR (from Delftia, Burkholderia, Campylobacter
and Chlostridium) are likely misannotated based on their place-
ment within this branch.
As demonstrated in a previous phylogenetic analysis [2],
PSMR proteins form small branches within both the SMP andSUG clusters. For example, PSMR members that have not
demonstrated drug resistance, such as YvaD and YvdS [2],
appear to cluster in outer branches at either side of the SUG
group (Fig. 1). However, YvdR is observed within the SUG
cluster, suggesting that this protein shares a much closer rela-
tionship to other SUG proteins than its partner YvdS. The
multidrug resistance conferring PSMR proteins, EbrAB, show a
tight cluster in a small branch towards the end of the SMP
cluster, adjacent to the SUG branch suggesting evolutionary
relatedness to both subclasses. The YdgEF pair appears to be
split apart, where YdgF resides within the SMP branch and
YdgE groups together with the EbrA branches. The remaining
multidrug-resistant PSMR proteins, YkkC and YkkD [20], can
be observed on branches at each end of the SUG cluster. This
suggests that they share a closer evolutionary relationship to
SUGmembers than to SMP proteins in opposition to their broad
drug resistance phenotype. Altogether, this indicates that PSMR
proteins should not be categorized within either SMP or SUG
subclasses solely on the basis of multidrug resistance. Hence,
we suggest that the PSMR proteins are worthy of their own
subclass designation.
7. SMR protein family drug resistance
As their name implies, the SMR protein family is renowned
for their ability to confer resistance to a variety of quaternary
ammonium compounds and cationic dyes to the host organism.
Commonly identified substrates of SMR proteins include QACs
such as methyl viologen (MV), tetraphenylphosphonium (TPP),
benzalkonium (Bz), cetyltrimethylammonium bromide (CTAB),
cetylpyridinium chloride (CTPC) [2,21,50,52,56,68,71,98,111]
and interchelating dyes such as ethidium bromide (Et), acrifla-
vine (Ac)/proflavin (Pro), crystal violet (CV), pyronine Y (PY),
and safranin O (SO) [2–4,17,20,21,47,49,50,52,56,59,68,71,75,
76,97,98,111] (for examples of compounds, see Fig. 3). QAC
resistance has been demonstrated for SMR members represent-
ing SMP, PSMR, and SUG subclasses but each class differs
based on their conferred resistance phenotypes to particular
QAC substrates.
Despite conferring host resistance to a wide range of QAC
and cationic dyes, members within the SMP subclass also
confer unique resistance profiles for particular compounds. For
example, SMP homologue Sau-Smr demonstrated much higher
minimum inhibitory concentration (MIC) values for the dyes
rhodamine 6G (R6G) and CV than Eco-EmrE but Eco-EmrE
conferred greater host resistance to Ac. QacJ had a Bz MIC that
was higher than isogenic recombinants expressing Sau-Smr,
QacG, or QacH [56]. Both QacE and QacH conferred high-level
Et resistance and low-level Pro resistance to its host bacteria,
thus differing phenotypically from other SMR homologues such
as Sau-Smr and QacG [49] (Table 2).
Over-expressed PSMR members, EbrAB and YkkCD, also
possess unique resistance profiles from each other. YkkCD
promoted much higher resistance to dyes such as Et and PY in
comparison to EbrAB which conferred much lower host resis-
tance to all drugs tested [20,97]. Other PSMR homologues such
as YvaE confer high levels of resistance to Et and Bz and
Fig. 3. Lipophilic substrates commonly used for SMR protein experiments.
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MIC values for other PSMR proteins. However, not all PSMR
proteins have demonstrated reproducible resistance profiles.
Single and co-expression experiments of the ydgEF pair per-
formed by Ninio et al. [26] using E. coli host strains JM109 and
TA15 were incapable of conferring host drug resistance in
contrast to experiments performed by Nishino and Yamaguchi
[98] who demonstrated host resistance to a variety of QACs and
cationic dyes by E. coli strain KAM3. This may suggest that the
drug resistance phenotype, conferred by the cloned YdgEF pair,
is conditional to the host strain (Table 2).
Another interesting trend in SMR resistance can be observed
for SMP proteins expressed using high copy plasmids with lacZ
or T7 promoters. Drug resistance experiments of SMP homo-
logues yielded lower MIC values for strains that expressed SMR
genes using their endogenous promoters (Table 2). For example,
Eco-EmrE and QacE both show much higher MIC values to
compounds such as Et, CV, and TPP in strains using high
expression plasmid systems versus expression under its native
promoter [3,4,21,98,111]. Furthermore, expression of SMP pro-
teins by its endogenous promoter can also result in variable QAC
and dye MIC values (for examples, see Sau-Smr; Table 2). This
suggests that the host strain harbouring the recombinant plasmid
may also play an important role when determining MIC values
[17,21,49,56,68,71].
In contrast to SMP proteins and other SUG members, Eco-
SugE is the only member of the SUG subclass that has conferred
resistance to only CTAB and CTPC when over-expressed in
E. coli [87]. Mutagenesis of four conserved key residues (H24,
M39, I43, and A44) in Cfr-SugE resulted in mutants that werehypersensitive to QACs and dye compounds suggesting that
single mutations can convert SugE into multidrug importers
[88]. Generally, SUG proteins have been reported to lack trans-
port activity altogether [1], but taking experiments involving
Eco-SugE and Cfr-SugE into consideration [87,88], a more
likely conclusion is that they transport an as of yet unidentified
substrate perhaps involved in chaperone activity (Table 2).
Apart fromQACs and cationic dyes, SMR proteins have been
tested for their ability to confer resistance to a variety of other
compounds. Isogenic recombinants, Sau-Smr and Eco-EmrE,
have promoted host resistance to β-lactam antibiotics such as
ampicillin, macrolides such as erythromycin, and tetracycline
[17,73,98]. Other drug resistance phenotypes that have reported
SMR involvement include the dihydrofolate inhibitor trimeth-
oprim [17]; aminoglycosides, amikacin [35]; and the glycopep-
tide antibiotic, vancomycin [98]. The ability to confer resistance
to β-lactam antibiotics by SMR proteins is complicated, since
experimental evidence has demonstrated both host resistance
and susceptibility to these drugs when SMR gene products are
expressed under varying conditions [29,73,98,112]. This
strongly suggests that the host strain and expression conditions
may have a large influence on SMR antibiotic resistance pheno-
types. SMR proteins have also conferred resistance to lipophilic
anion compounds such as the detergent sodium dodecyl sulfate
(SDS), the antimicrobial phosphonomycin [20,98], and neutral
drugs such as chloramphenicol [20], indicating that SMR pro-
teins are involved in the transport of substances in addition to
lipophilic cations. Experiments examining the transport of the
hydrophobic QACs TPP+ and MV2+ by Eco-EmrE indicate that
although transport energetics for each compound differ, both
compounds require PMF and have the same H+:drug stoichi-
ometry [113]. The recent characterization of PSMR homologues
NepA and NepB (both proteins group within the PSMR/EbrAB
branch; Fig. 1) from the pAO1 plasmid of A. nicotinovorans
demonstrated their involvement in nicotine transport and cata-
bolism via PMF [106]. Only co-accumulation of both NepAB
proteins permitted the export of this potentially toxic alkaloid
compound providing support for SMR-mediated transport of
other metabolic compounds. Altogether, these findings suggest
that the lipophilic/ringed nature of the target SMR substrate may
be of greater importance than its charge.
8. SMR protein alignment and conserved TM motifs
Numerous sequence alignments have been performed using
select SMRhomologues aswell as larger SMR sequence datasets
[1,20,26,27,75,114]. To update these alignments, a subset of 101
annotated SMR homologues representing members from each
SMR subclass was compiled to identify conserved and semi-
conserved residues. Alignments using ClustalW [107,108,115]
have demonstrated that SMR subclasses SMP and SUG possess
unique conserved residuemotifs in each of the four predicted TM
strands of the proteins (Table 3; Supplementary Fig. 1).
Residue conservation within SMR protein TM strand 1
(TM1) was highest within the alignment. High conservation
was also noted within TM strand 4 among all SMR proteins
examined, emphasizing the importance of these strands for all
Table 2
SMR protein family resistance to a variety of dyes and drugs
Organism
SMR Dyes Quaternary ammonium compounds SDS Antibiotic and bacteriostatic drugs Reference
Et Ac/Pro CV R6G SO PY CTAB Bz MV CTPC TPP TPA AKPG Tri Amp Ery Tet Chl Van
Staphylococcus aureus Sau-smr a 80–800 25–60 20 N800 nd nd 4–100 3.5–80 nd 80 nd 600 nd nd nd nd nd nd nd nd [21,68,49,
56,71]
Staphylococcus epidermidis Sau-smr a 20–60 NR nd NR nd nd nd nd nd nd nd nd nd nd 256 64 N256 64 nd nd [17]
Escherichia coli BL21(DE3) Hsa-smr N500 b N120 b nd nd nd nd nd nd 200 b nd nd nd nd nd nd nd nd nd nd nd [76]
Escherichia coli JM109 Eco-EmrE N600 nd nd nd nd nd nd nd 400 b nd N200 nd nd nd nd nd nd 2 NR nd [3,4]
Escherichia coli KAM3 Eco-EmrE a 100 200 3.13 6.26 nd nd nd 6.25 200 nd 6.25 nd 50 nd 3.13 nd 3.13 0.39 0.39 200 [98]
Escherichia coli Mse-Mmr a 40 100 nd nd 30 150 nd nd nd nd 5 nd nd nd nd nd 60 nd nd nd [75]
Escherichia coli BHB2600 qacE a 800 30 60 N800 nd nd 60 20 nd 40 nd 600 nd nd nd nd nd nd nd nd [21]
Escherichia coli C600 qacE ≥400 50 25 nd 400 25 6.25 3.13 nd nd nd nd nd 50 nd nd nd nd nd nd [111]
Escherichia coli
BHB2600/C600
qacEΔ1 a 100–400 40–50 10–25 N800 400 25 6.25–100 3.1–80 nd 80 nd 600 nd 50 nd nd nd nd nd nd [21,52,111]
Pseudomonas sp. B13
GFP1/Escherichia coli JM83
qacF a nd nd nd nd nd nd 15–400 15 nd nd nd nd nd nd nd N128 nd nd nd nd [47,59]
Staphylococcus aureus RN4220 qacH a 440 60 nd nd nd nd 8 3.5 nd nd nd nd nd nd nd nd nd nd nd nd [49,56]
Staphylococcus aureus RN4220 qacG a 80 25 nd nd nd nd 15.5 5–10 nd nd 30 nd nd nd nd nd nd nd nd nd [49,50,56]
Staphylococcus aureus qacJ a nd nd nd nd nd nd 16 6 nd nd nd nd nd nd nd nd nd nd nd nd [56]
PSMR
Escherichia coli DH5α Bsu-yvaE 500 nd 12 nd nd 32 nd 50 nd 100 nd 800 nd nd nd nd nd nd nd nd [2]
Escherichia coli DH5α Bsu-ykkC
Bsu-ykkD
50–2000 500 2–50 nd nd 8–500 nd 50 1000 80 nd 500–1000 nd nd nd nd nd 2 10 nd [2,20]
Escherichia coli KAM3/DH5α
Bacillus subtillis ISW1214
Bsu-ebrA
Bsu-ebrB
0.5–16 0.14–4 0.01 1 nd 8 0.007 0.014 nd 0.003 1.5 1.5 nd nd nd nd 0.25 nd 0.5 nd [97,135]
Escherichia coli KAM3 ydgE a
ydgF a
12.5 12.5 1.56 6.25 nd nd nd 3.13 100 nd 6.25 nd 100 nd 3.13 nd 3.13 0.39 0.39 200 [98]
SUG
Escherichia coli
DH5α/TOP10F'
sugE a NR nd NR nd nd NR 120 NR nd 160 nd NR nd nd nd nd nd nd nd nd [87]
Resistance values are listed in milligram per milliliter concentrations unless otherwise stated.
Drug and dye abbreviations are as follows: methyl viologen (MV), tetraphenylphosphonium (TPP), tetraphenylarsonium (TPA), benzalkonium chloride (Bz), cetyltrimethylammonium bromide (CTAB), cetylpyridinium
chloride (CTPC), acriflavine (Ac)/proflavin (Pro), ethidium bromide (Et), crystal violet (CV), safranin O (SO), pyronine Y (PY), rhodamine 6G (R6G), sodium dodecyl sulfate (SDS), alkylpolyaminoethylglycine HCl
(AKPG), trimethoprim (Tri), ampicillin (Amp), erythromycin (Ery), tetracycline (Tet), chloramphenicol (Chl), and vancomycin (Van).
nd, not determined and NR, not resistant.
a Experssion of gene using native promoter.
b Values listed in mM.
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Table 3
SMR protein consensus motifs determined for each SMR subclass from a protein alignment of 101 SMR sequences
SMR class TM/Loop (L) Consensus motif
SMR TM1 [F/W/Y]-x-[F/W/Y]-[L/M/V/I]-(x2/6)-[A/S/G]-[I/V/G/A]-x2-E-x2-[G/W/A/F]-[T/A/V/S/N]-x2-[L/M]
SMP [F/W/Y]-x-[F/W/Y]-[L/M/V/I]-x2-[A/S/G]-[I/V]-x2-E-x2-[G/A/S]-[T/S/N]-x2-[L/M]
SUG [F/W/Y]-x-[F/W/Y]-[L/M/V/I]-x2-[A/S/G]-[G/A]-x2-E-x2-[W/F]-[A/V]-x2-[L/M]
PSMR [F/W/Y]-x-[F/W/Y]-[L/M/V/I]-(x2/6)-[A/S/G]-[I/V/G/A]-x2-E-x2-[G/W/A/F]-[T/A/V/S/N a]-x2-[L/M]
SMR L1 [K/R/P]-x-[S/T/A]-x3-[R/K]
SMP [K/R/P]-x-[S/T/A]-[E/D/H]-[G]-[F]-[T/S]-[R/K]-[L/P]
SUG [K/R/P]-x-[S/T/A]-[E/D/H]-[G]-[F]-[T/S]-[R/K]-[L/P]
PSMR [K/R/P]-x-[S/T/A]-x3-[K b/R b/D c/E c]-[R/K]-x
SMR TM2 [P/G] d-x10-[A/S/C]-x3-[L/F]-x4-[K/R/Q]-x-[I/L/V/M]
SMP [P/G]-[S/T]-x6-[Y/F]-x2-[A/S/C]-[F/Y/L/M]-[Y/F]-x-[L/F]-x4-[R/K/Q]-x-[I/L/V/M]
SUG [P/G]-[S/T]-x6-[Y/F] d-x2-[A/S/C]-[F/Y/L/M]-[Y/F] d-x-[L/F]-x4-[R/K/Q]-x-[I/L/V/M]
SMR L2 [P/D/E/A]-x-[G/S/N]
SMP [P/D/A]-x-[G/S/N]
SUG [P/D/A]-x-[G/S/N]
PSMR [D/E/A]-x-[S e/N b/G]
SMR TM3 x-[A/V/S]-Y-[A/G/S]-[I/V/L]-W-x-[G/A]-x-[G/A]-x7-[G/A/S]
SMP [V/I/L]-[A/V/S]-Y-[A/G/S]-[I/V/L]-W-[S/A]-[G/A]-x-[G/A]-x7-[G/A/S]
SUG [T]-[A/V/S]-Y-[A/G/S]-[I/L/V]-W-[T]-[G/A]-[I]-[G/A]-x7-[G/A/S]
PSMR x-[A/V/S]-Y-[A/G/S]-[I/V/L]-W-[G/E]-[G/A]-x-[G/A]-x7-[G/A/S]
SMR L3 [E/D/Q]-x2-[D/N/S/T]
SMP [Q/E/D]-x2-[D/N] f
SUG [E/D/Q]-x2-[S/T] g
SMR TM4 x3-[G/S/L/F]-[I/L/V/M]-x-[L/I/V/M/F]-[I/V/L/M]-x2-[G/A/S]-[V/I/A/M]-[I/V/A/L]-x-[L/I/V/M]-x
SMP [A/G/S] d-x2-[G/S/L/F]-[I/L/V/M]-x-[L/I/V/M/F]-[I/V/L/M]-x2-[G/A/S]-[V/I/A/M]-[I/V/A/L]-[V/L/I] d-
[L/I/V/M]-[N/H/Q] d
SUG [K/R] d-x2-[G/S/L/F]-[I/L/V/M]-x-[L/I/V/M/F]-[I/V/L/M]-x2-[G/A/S]-[V/I/A/M]-[I/V/A/L]-[G/T/S] d-
[L/I/V/M]-[K/R]
PSMR [A] h/G] a/K] i/R i] d-x2-[G/S/L/F]-[I/L/V/M]-x-[L/I/V/M/F]-[I/V/L/M]-x2-[G/A/S]-[V/I/A/M]-[I/V/A/L]-[V c/L c/I c/G j/S j/T j] d-[L/I/V/
M]-[N k/H k/K l/R l] d
mResidue commonly found for YdgF only.
a Residue commonly found for YdgE only.
b Residue commonly found for YkkCD and YvdRS only.
c Residue commonly found for YdgEF only.
d Indicates residues with semi-conservation (60–80%) within an alignment of 101 SMR proteins.
e Residue commonly found for YdgEF and YkkCD only.
f Motif found in EbrB and YvdRS.
g Motif found in EbrB and YvdRS.
h Residue commonly found for EbrAB and YvaE only.
i Residue found in YkkCD, YvdRS, and YdgF.
j Residue found in EbrAB, YvaED, and YkkCD.
k Motif found in EbrAB and YvaE.
l Motif found in YkkCD, YvdRS, and YdgEF.
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TM strands from this alignment are in general agreement to
previously described TMmotifs [1,26,27,114]. Excluding TM1,
each TM and loop consensus motif representing the SMR
protein family was not as strongly conserved as previously
reported [1,20,26,27,75,114].
TM and loop motifs for SMP and SUG subclass proteins
demonstrated high residue consensus at particular positions
within the motif specific for each group. Although unique con-
sensus motif trends can be observed for SMP and SUG sub-
classes within each TM segment, TM4 in particular possessed
the most sequence subclass specificity. To illustrate this point,
different residue biases can be noted for SUG or SMP
homologues. In TM4, for example, SUG proteins appear to
have more positively charged residues flanking each end of the
TM motif than SMP proteins, a residue bias that may have
functional importance, perhaps for its topology based on vonHeijne's positive inside rule (as reviewed by [116]). The
presence or absence of other residues such as aromatics and Ala
or Gly at positions 14–15 in the TM1 motifs of SUG or SMP
likely influences conformation and function of each SMR
protein class. An argument supporting this observation can be
shown for Eco-EmrE Cys cross-link and accessibility labeling
experiments that demonstrate the importance of these residues
for both the binding pocket and dimerization [117–119].
Overall, PSMR proteins within our alignment followed both
SMP and SUG TMmotifs and often mirrored their placement in
the SMR protein phylogenetic tree (Fig. 1; Table 3). Despite
PSMR protein partitioning into both SMP and SUG consensus
motifs, residues unique to PSMR proteins could only be found
within loop 1 (Table 3). The importance of both loop and C-
terminus tail regions has been previously demonstrated in site-
directed mutagenesis experiments of B. subtilis EbrAB that
examined heteromeric transport activity of PSMR protein pairs
Fig. 4. A ribbon model representing the asymmetric Eco-EmrE homodimer
at 7.5 Å based on the putative assignment to the three-dimensional cryo-EM
structure [61,62]. Each α-helix TM strand from either Eco-EmrE monomer
(monomer 1′ and monomer 2) is numbered adjacent to each ribbon (grey). The
ligand, TPP, is shown bound to the asymmetric homodimer according to the
cryo-EM data by [62,64] by the four-ringed stick diagram (black). This ribbon
model was constructed using the online WebMol-java PDB browser [157]
according to the EmrE dimer backbone carbon-atom assignment [61–64]
available from the Protein Data Bank (PDB number 2i68).
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coli YdgEF pair also changed their membrane orientation [102].
Besides loop 1, other conserved residues that are specific to
PSMR pairs or individual PSMRs can also be found among the
4 TM strands and remaining loops. This emphasizes that a
particular residue position likely plays a specific role that is
tailored to each subgroup or protein.
In summary, unique consensus motifs exist within the SMR
family specific for each SMR protein subclass. It is important to
note that integron and plasmid encoded QacE, QacEΔ1, QacF,
QacH, QacJ align well with their chromosomally encoded SMP
counterparts. PSMR proteins EbrAB, YdgEF, and YvaE often
shared motif positions within the SMP protein subclass. The
remaining PSMR proteins YkkCD and YvdRS grouped together
below the SUG homologues indicating that they share closer
relationship with members of the SUG protein subclass than
SMP members. The updated consensus motifs (Table 3)
highlight the functional differences observed within this protein
family, providing strong support for our current phylogenetic
analysis (Fig. 1) and three SMR subclass designation.
9. SMR protein membrane topology: single versus dual
orientation
When it comes to structural topology of the SMR protein
family, the only feature that is universally agreed upon is the 4
TM strand α-helix arrangement of these proteins. All SMR
protein family members consist of four predicted TM α-helices,
similar to the topology of Eco-EmrE and Eco-SugE based
on hydropathy plot analysis and secondary structure predictions
[1,7,26,27,89,114] (Fig. 2). The predominately α-helical nature
of Eco-EmrE (up to 80% α-helix) has also been confirmed
using Fourier transform infrared spectroscopy (FTIR) [120,121]
and circular dichroism (CD) spectropolarimetry [90,122] in
various membrane mimetics. Nuclear magnetic resonance
(NMR) studies have examined separately expressed TM
segments 1 and 3 in SDS [123]. This high α-helix content has
also been observed for H. salinarum Hsmr protein solubilized
in SDS analyzed by CD spectropolarimetry [77].
The arrangement of SMR protein TM strands within the
protein complex has not yet been resolved. SMR proteins were
proposed to be arranged in a four helix bundle based on the
results of various site-directed mutagenesis [4,124,125], chemi-
cal cross-linking [118,126], and biophysical analyses of Eco-
EmrE protein and its peptide fragments [120,121,123]. A four
helix bundle arrangement for the Archaeal homologue, Hsmr,
was also proposed based on CD spectropolarimetry of TM
peptide fragments and molecular dynamics modeling of the
entire protein [77,127]. These studies also suggested that TM
strands could be arranged in two possible bundle conformations
within the dimer that centred around TM4 resulting in a proposed
two-faced TM strand model [77]. Additionally, three-dimension-
al cryo-EM structures of Eco-EmrE both bound and unbound by
substrate, ascertained that the TM strands are arranged in a
asymmetrical fashion with a quasi-symmetry axis within the
observed homodimer [61,62,64] (Fig. 4). In cryo-EM structures,
four helix bundles were observed only in tetramers, where eachbundle was formed between each dimer [62,64]. Perhaps this TM
arrangement reflects the results from spin labeling experiments of
Eco-EmrE TM1 in detergent which revealed the existence of a 2-
fold symmetry axis in the protein [128]. Taken together, it seems
that SMR protein TM arrangements are sensitive to the
environmental conditions used for conformational studies.
The topology and orientation of these proteins within the
inner membrane have sparked an interesting and often contro-
versial debate within the SMR protein field and the evolution of
transporters. SMR proteins have been reported to adopt a single
uni-directional orientation within the membrane as well as a bi-
directional orientation where the proteins of a homodimer have
opposite topologies (as described in [116,129]). Evidence
supporting a single orientation of the SMR protein family
comes from a variety of protein fusion and protein cross-linking
experiments in addition to in silico modeling. Topology
mapping of Sau-Smr using a series of alkaline phosphatase
(PhoA) and β-galactosidase (LacZ) fusions to truncated poly-
peptides revealed that the N-terminus and predicted loop 2 were
exposed to the cytoplasm but could not accurately determine the
C-terminus orientation of the protein [68]. Maltose binding
protein and β-lactamase protein fusions to both the N- and C-
terminus of Eco-EmrE and Cfr-SugE proteins have been de-
monstrated to face the same cytoplasmic side of the membrane
supporting a similar single topology for other SMR homologues
[88]. A cytoplasmic location for the C-terminus was also con-
firmed for C-terminal His-tagged cysteine lacking Eco-EmrE
variants that were probed in vivo using a His-probe horse
radish peroxidase system as well as by the cross-linking ability
of Cys replacement mutants [130]. A single topology of
SMR oligomers was also demonstrated by cysteine cross-link
experiments of dimerized Eco-EmrE variants with Cys replace-
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cross-linking [126]. In these experiments, only Eco-EmrE Cys
replacements that promoted a single parallel orientation could
be cross-linked and only these cross-linked EmrE proteins
demonstrated substrate transport activity after reconstitution
into proteoliposomes.
Finally, molecular dynamics models of SMR homologues
Hsmr and Eco-EmrE demonstrated that a single orientation
within artificial lipid membranes is energetically favorable for
an oligomeric complex [77,127]. A single topology was also
demonstrated for PSMR protein YdgE of the YdgEF complex,
using C-terminus reporter protein fusions in vivo. These indi-
cated that the C-terminus is located within the cytoplasm [99].
Taken together, these experiments provide a convincing argu-
ment for a single SMR protein topology, where both N- and C-
termini face the cytoplasm (Nin−Cin).
A dual topology for all SMR proteins in the membrane has
been proposed according to experimental evidence of SMR
protein C-terminus reporter fusions [101–103] and based on
high-resolution structures of Eco-EmrE [61–64]. The possibility
of a dual orientation for Eco-EmrE in the inner membrane was
first proposed by Tate and colleagues, after three-dimensional
cryo-EM data were best fit using an asymmetrically arranged
homodimer of Eco-EmrE protein [62–64]. Although this struc-
ture lacked sufficient resolution to assign precise amino acid
positions, an asymmetrical EmrE dimer was suggested and the
argument for an antiparallel arrangement by each monomer was
proposed to explain this asymmetry. The three-dimensional
X-ray diffraction structures of Ma and Chang [65,66] and
subsequent structure with bound ligand by Pornillos et al. [67]
has also been cited in support of a dual topology of the EmrE
dimer. Unfortunately, the calculated assignment of the X-ray
diffraction structure was found to be incorrect and the EmrE
structure (PDB ID number 1S7B, 2F2M) has been recently
retracted [131]. We wait in anticipation for these structures to be
recalculated. However, the proteins were crystallized in an odd
detergent and we now know the detergent influences the struc-
ture significantly [121].
Antiparallel arrangements of membrane proteins were
initially predicted based on the ‘positive-inside’ rule determined
by von Heijne in 1986 [132,133]. Based on this rule, dual
insertion orientations of E. coli SMR proteins were predicted
for all E. coli SMR homologues and tested using C-terminus
reporter protein fusion experiments. SMR proteins, Eco-EmrE
and Eco-SugE, have a net K and R bias (K+R) close to zero,
unlike PSMR proteins Eco-YdgE and Eco-YdgF which have
high oppositely charged K/R biases. This lack of positive inside
bias in part leads to the prediction that all of these proteins adopt
a possible dual topology [100,102,103]. Global topology map-
ping of 601 E. coli inner membrane proteins, including all four
SMR homologues using C-terminus green fluorescent protein
(GFP) fusions identified that all four SMR proteins (in addition
to predicted dual topology protein pair YdgQ/YdgL) yielded
intermediate fluorescent signals of GFP which was interpreted
as a mixed topology [100]. Site-directed mutagenesis of specific
positively charged residues in each of the four SMR homo-
logues that resulted in alterations to their predicted positivecharge bias, in many cases altered the topology of the variant
protein relative to the wild-type fusion protein [102,103]. In
particular, Eco-EmrE conferred host drug resistance when mu-
tants promoting only EmrE (Nin−Cin) and EmrE (Nout−Cout)
topologies were co-expressed [103]. Hence, the results of these
studies suggest that a mixed Nin−Cin and Nout−Cout orientation
of Eco-SugE and Eco-EmrE may exist within the inner mem-
brane, whereas the PSMR pair YdgE and YdgF has fixed
Nout−Cout and Nin−Cin topologies, respectively. It should be
noted that a dual topology arrangement of Eco-EmrE has not
been directly shown to have transport activity leading some to
suggest that it is a crystallization artifact [126]. The SMR
fusion protein experiments by Rapp et al. [102,103] have also
contrasted previous topology mapping results which deter-
mined that Eco-YdgE C-terminus had a cytoplasmic location
[99].
Biochemical evidence supporting a fixed dual topology of
PSMR proteins has been recently demonstrated using cysteine-
scanning mutagenesis experiments of the PSMR pair Bsu-EbrA
and Bsu-EbrB [134]. Fluorescein-5-maleimide (NEM-fluores-
cein) labeling experiments of E. coli cells co-accumulating
cysteine variants of EbrA and EbrB proteins in predicted loops
and termini, demonstrated labeling from both sides of the
membrane regardless of its intactness supporting a mixed topo-
logy of the heterooligomer. Similar to observations made for
Eco-YdgEF, the orientation of each Bsu-EbrA (Nout−Cout) and
Bsu-EbrB (Nin−Cin) protein in the membrane obeys its ‘posi-
tive-inside’ prediction [134,135]. This provides strong support
for an antiparallel topology of PSMR proteins.
When considering all of the experiments performed, evidence
supporting both a single and dual topology for the SMR protein
family can be argued making this an essential area of research to
address before an accurate structure can be elucidated.
10. SMR protein oligomerization
Accurate determination of the multimeric state of SMR pro-
teins is critical since numerous experiments have suggested that
SMR proteins demonstrate transport activity when oligomer-
ized [4,27,97,126,136]. In general, SMR proteins are expected
to form homooligomers, similar to Eco-EmrE [2], while the
newly defined PSMR proteins (Gram-negative SMR homo-
logues Eco-YdgEF and Gram-positive SMR homologues Bsu-
EbrAB, Bsu-YkkCD, Bsu-YvdRS and Bsu-YvaDE) form hete-
rooligomers [2,20,27,97,135]. Thus far, only Bsu-EbrAB have
been examined experimentally. Oligomeric characterization of
SUG proteins have not been performed to date but due to their
isogenic transport function they likely function as homooligo-
mers [87,88].
Unifying all the structural data collected for SMR proteins
becomes increasingly complicated due to the variety of condi-
tions under which they are expressed, isolated, and solubilized.
Accurate determination of membrane protein oligomeric states
is challenging in its own right making it difficult to decide on
the validity of a given technique. In many cases, the method of
protein purification or modifications made to the protein to
facilitate its over-accumulation may be an explanation for the
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larly pertinent for many experiments examining the oligomeric
state of SMR proteins. The addition of a purification tag to the
protein (for example, see [4]), the method of extraction from the
cell using tag-dependent chromatography in detergent or by
organic solvents (for example, see [5]) may contribute to vari-
ation in SMR protein multimerization. Hence, the oligomeric
states of SMR proteins have been difficult to accurately deter-
mine both in vitro and in vivo. A variety of bioinformatic and
biochemical/biophysical experiments have been performed to
identify its true multimeric state.
Eco-EmrE has been the archetypical homooligomer based on
the large amount of experimental data obtained throughout its
study. This SMR protein is believed to exist as a homooligomer
[63,136–138] but experiments of detergent solubilized EmrE
and SugE monomers indicate that substrate binding may not be
oligomer-dependent [139,140]. The multimeric state of EmrE
has been shown to vary from monomers [6,90,118], to dimers
[61–64,118,136,137,141], trimers [4,114,142] and tetramers
and/or dimers of dimers [62,64,65,67,137] depending on
experimental conditions. Although EmrE multimerization has
been confirmed in experiments involving intact cell membranes
[118,130], its functional multimeric state in vivo has not been
confirmed.
Based on numerous biophysical experiments of Eco-EmrE, the
most frequently determined multimeric state of homooligomeric
SMR proteins is a dimer. EmrE dimers predominate when
solubilized in the detergent, dodecyl-β-D-maltoside (DDM), and
have been detected from experiments such as chemical cross-link
assays [118,126], electrospray mass spectroscopy (ESI) analysis
[143], size exclusion chromatography (SEC) HPLC, ultracentri-
fugation [141], functional complementation experiments and
pull-down assays [137], and fluorescence resonance energy
transfer analysis [77]. Reconstitution of detergent solubilized
Eco-EmrE into artificial membranes has also yielded protein
dimers as demonstrated by cryo-EMof three-dimensional crystals
[61,62,64]. In silico modeling of Eco-EmrE and the Archaeal
Hsmr monomers have also suggested stable dimer formation
within an artificial lipid environment [77,127].
Higher multimeric states of homooligomeric SMR proteins
namely, trimers and tetramers, have also been reported for
experiments involving Eco-EmrE. SMR protein trimers have
been observed upon SDS-PAGE gels of the purified C-terminus
FLAG-tagged Sau-Smr in detergents, such as DDM [22].
Trimers are also proposed to be the SMR functional complex
based on the analysis of functional inactivation (negative domi-
nance) assays that used mixed oligomers composed of an in-
active monomer of Eco-EmrE combined with functional Eco-
EmrE subunits [4]. Further support for a functional trimer was
based on the results from [3H]TPP binding assays of Eco-EmrE
which suggested that 3 mol of EmrE was necessary to bind 1
mol substrate [142]. Molecular dynamics modeling of Eco-
EmrE built using conserved residue data also proposed a tri-
meric model for the protein composed of four helix bundles that
were stabilized by the third highly conserved TM strand from
each monomer [114]. The difficulty of achieving high transport
activity in EmrE preparations and the exact determination ofEmrE concentrations in these experiments may explain a lack of
EmrE trimers observed using other direct experimental methods
such as chemical cross-linking analysis.
SMR protein tetramers have been identified primarily from
cryo-EM frozen hydrated crystals and from chemical cross-link
experiments of C-terminus His-tagged Eco-EmrE. Analysis of
cryo-EM crystals [62,64] demonstrated Eco-EmrE tetramers
were present as an arrangement of two protein dimers. Both
asymmetric EmrE dimers were arranged in a 2-fold axis of
symmetry in the plane of the phospholipid membrane (Fig. 4).
Unfortunately, insufficient resolution (7 Å) precludes the accu-
rate determination of protein side chains that are necessary to
determine which regions of the protein are directly involved in
the tetramerization [62,64]. Putative assignment of the carbon
atom backbone to this dimer of dimers arrangement has also
been observed in experiments using cell free expression of Eco-
EmrE in DDM where detergent solubilized cysteine-lacking
Eco-EmrE protein dimers were capable of being chemically
cross-linked together via a cysteine replacement (K22C) [137].
This result demonstrated potential for a tetrameric state in the
membrane. The cross-link ability of Eco-EmrE K22C indicates
that loop 1 likely plays a role by interacting with other sub-
units and by stabilizing higher oligomeric arrangements of the
protein [137].
Loops have also demonstrated their importance for the
oligomerization of heterooligomeric PSMR proteins, namely
Bsu-EbrA and Bsu-EbrB. Like other paired SMR proteins, such
as Eco-YdgEF or Bsu-YkkCD, Bsu-EbrA and Bsu-EbrB pro-
teins have only conferred host resistance when co-expressed
within the cell indicating that both proteins are necessary for
efflux activity [2,20,97,135]. Based on the requirement for the
presence of both proteins to confer a drug resistance phenotype,
these PSMR pairs have been suggested to form functional
heterooligomers with each other [2,39]. The number of subunits
of each SMR pair that compose this heterooligomer has not
been determined to date but “pull-down” binding assays of His-
tagged Bsu-EbrA determined direct interaction of untagged
Bsu-EbrB at potentially equimolar amounts [135]. Regions
from each Bsu-EbrAB substituent involved in this multimeriza-
tion have been explored [27]. Hydrophilic loops and C-terminal
regions of PSMR proteins differ from their isogenic homo-
oligomeric counterparts based on the increased residue length.
Replacement mutagenesis experiments which truncated loops 1
and 3 as well as the C-terminus of each Bsu-EbrAB pair was
performed and assayed for their ability to confer antiseptic
resistance to host cells when expressed individually [27]. Trun-
cation of both the hydrophilic loops and the C-terminus in each
protein pair conferred a drug resistance phenotype to host cells
expressing each mutant individually. These results suggest that
hydrophilic loops and C-termini are involved in paired SMR
protein heterooligomerization but that they may also play an
important role in the specificity of subunit oligomerization by
homooligomeric SMR proteins.
SMR protein oligomeric specificity has been examined by
radiolabelled Eco-EmrE “pull-down” binding assays involving
His-tagged SMR homologues, Pae-EmrE, Bpe-EmrE, Mtu-
Mmr, and the Eco-YdgE and Eco-YdgF pair [26]. Eco-EmrE
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high sequence identity to Eco-EmrE namely Pae-EmrE (45%
identity) and Bpe-EmrE (58% identity) strongly interacted with
radiolabelled Eco-EmrE. However, paired SMR homologues
Eco-YdgE (33% identity to Eco-EmrE) and Eco-YdgF (32%
identity to Eco-EmrE) and the SMR homologue Mtu-Mmr
(41% identity to EmrE) failed to interact with radiolabelled Eco-
EmrE. Those SMR homologues that did not interact with Eco-
EmrE also demonstrated high residue variation within the loop
and C-terminus regions suggesting that oligomerization of these
proteins is specific for these regions.
11. SMR protein drug transport mechanism
SMR protein substrate efflux is energy dependent and is
driven by PMF based on experiments using Sau-Smr performed
first by Grinius and Goldberg [18,22]. In these experiments,
Sau-Smr reconstituted into proteoliposomes demonstrated TPP
efflux via an electrochemical proton gradient. These results
were confirmed for the SMR homologue, Eco-EmrE, using
similar experimental conditions [3,4]. As such, SMR proteins
have been classified as proton-dependent multidrug efflux
systems [23]. SMR proteins have demonstrated the transport of
negatively charged and neutral compounds aside from QACs
[20,98]. Studies focusing on the substrate transport energetics of
Eco-EmrE have revealed that the energy requirements for
transport differ depending on the nature of the compound.
Transport of monovalent lipophilic cations, such as the mem-
brane permeant TPP, appears to be electrogenic and requires
charge movement for efflux, whereas transport of divalent
lipophilic cations such as MVare electrogenically neutral [113].
This finding suggests that the efflux of particular compounds
mediated by SMR protein is highly dependent on the energetic
state of the cell and the proton gradient across the membrane. It
may also offer hints for the variation in drug resistance by host
cells harbouring SMR proteins.
SMR proteins exhibit a variety of drug binding affinities with
KD values ranging from nM to μM that appear to be influenced
by their inherent sequence variation or the membrane mimetic
used for their examination (Table 4). Comparisons of radio-
labelled MVuptake rates between His-tagged SMR homologues
Pae-EmrE, Bpe-EmrE, and Mtu-Smr to Eco-EmrE reconstituted
into liposomes indicated that MV Km values were greater (3- to
5-fold) in all the SMR homologues excluding Eco-EmrE [26].
Variation in TPP binding affinity among the SMR proteins was
demonstrated and showed intermediate to low TPP binding
affinities in comparison to Eco-EmrE [26]. The halophilic
Archaeal SMR homologue Hsmr also demonstrated an interme-
diate TPP binding affinity compared to His-tagged Eco-EmrE
that could be modified under high and low salt concentrations
[76]. The differences in SMR homologue drug binding affinities
from those of Eco-EmrE highlight the sequence diversity among
the other characterized homologues. It suggests that SMR
homologues possess unique substrate profiles that may be
tailored to the activity of their host making them excellent
resources for comparative SMR protein structural studies and
transport mechanism characterization.SMR protein multimerization is suggested to be a require-
ment for active drug transport by SMR proteins, particularly for
members of the PSMR subclass [4,27,97,126,135–137]. Al-
though, monomeric SMR proteins can bind drugs with strong
affinity [6,139,140], an oligomeric complex is likely a neces-
sary part of drug transport by SMR proteins. However, this
assumption is primarily based on observations of other trans-
porter families which have greater than 10 TM strands and 4
TM strands would be considered insufficient. Substrate binding
of monomeric Eco-EmrE and Eco-SugE protein extracted from
cell membranes using organic solvents demonstrate μM range
KD drug affinities for a variety of drugs (that included TPP) after
their reconstitution into a variety of membrane mimetics (deter-
gents; DDM, octaethyleneglycol mono-n-dodecylether (C12E8),
SDS, and reconstituted into small unilamellar vesicles (SUV)
composed of E. coli lipid extract) and analysis by fluorescence
or by isothermal titration calorimetry (ITC) [6,139,140]. Based
on these studies, the stoichiometry of ligand to protein was
determined to be 1:1 independent of the membrane mimetic
environment. His-tagged Eco-EmrE (Eco-EmrE-His6) isolated
by Ni-affinity chromatography and solubilized in DDM de-
monstrated far more variation in drug to protein affinities (see
Table 3 and references therein). Examination of Eco-EmrE-His6
drug binding affinities has focused primarily on radioactively
labelled TPP binding only and has estimated KD values ranging
from nM [62,136,137,142] to μM [141]. Taken from these
studies, the stoichiometry of ligand to protein was much more
variable ranging from 1:2, 1:3, to 1:5 which differed according
to its determined oligomeric state [141,142] and upon recon-
stitution into phospholipid bilayers [62].
Variations in H+:SMR protein stoichiometry have also been
reported to vary from 1:1 [113,144], 1:2 [62], and 2:3 [142,145].
Hence, H+/drug binding affinities and stoichiometry appear to be
highly influenced by the experimental conditions and emphasize
the challenge that integral membrane proteins pose for study.
Ultimately, these experiments have demonstrated that the drug
binding affinity of SMR proteins is strong despite these many
differences.
12. The SMR protein ligand binding site: the significance of
conserved residues
Site-directed mutagenesis studies of both Sau-Smr and Eco-
EmrE identified that a single highly conserved negatively
charged glutamate residue (in Sau-Smr E13; E14 in Eco-EmrE)
within the first TM strand was essential for drug transport
activity [22,124,125,142]. SMR protein glutamate variants with
replacements that remove its negative charge (C or A residues)
reduce its ability to grow in a variety of toxic substrates such as
Et andMV [22,119] or completely eliminate host drug resistance
[124]. Site-directed SMR mutants that replaced Glu with Asp
also demonstrated a reduction in substrate transport rate by the
protein [125,135,142] and narrowed its host resistance to par-
ticular substrates [22,119]. In particular, studies of Eco-EmrE
have indicated that this residue is involved in the direct binding
of both substrate and proton proposing that this residue is the
primary active site constituent for SMR proteins [113,119,145].
Table 4
Ligand binding affinities and stoichiometry of the SMR protein family
SMR Purification method Membrane mimetic Experiment QAC/Dye KD (μM) Molar ratio of drug:SMR Reference
Eco-EmrE-myc-His6
a NCC 0.08% DDM ED [3H]TPP 0.01±0.003 1:3 [142]
Eco-EmrE-
(E25C/D84C)-His6
b
NCC 0.08% DDM SBA [3H]TPP 0.028 1:3 [125]
Eco-EmrE-His6
b NCC 0.8% DDM SBA [3H]TPP 0.0028±0.001 variable [136]
Eco-EmrE-His6
b NCC; delipidated 0.5% DDM SBA [3H]TPP 2.5±0.5 1:2 [141]
Eco-EmrE-His6
b NCC: not delipidated 0.5% DDM SBA [3H]TPP 10±2 1:2 [141]
Eco-EmrE-myc-His6
a NCC 0.1% DDM SBA [3H]TPP 0.0026 1:3 or 1:5 [62]
Eco-EmrE and
Eco-EmrE-His6
a
NCC 0.08% DDM SBA [3H]TPP 0.0023 nd [137]
Eco-EmrE OSE SUV ITC Et 5.5±2.1 1:1 [139]
MV 38.2±8.7
Pro 10.7±2.7
OSE SDS ITC Et 5.2±1.4 1:1 [139]
MV 5.4±1.2
Pro 4.5±0.8
TPP 4.8±0.8
OSE DDM ITC Et 6.3±1.0 1:1 [139]
MV 46.2±10.5
Pro 5.2±0.9
TPP 25.5±6.2
Eco-EmrE OSE 2% DDM Fluoro Et 6.81±0.53 nd [6]
MV 43.6±3.80
TPP 23.6±7.10
CTP 6.61±2.20
Eco-EmrE-His6
b NCC SUV MV DUA [14C]MV 260 c nd [26]
Hsmr-His6
b NCC 1% DDM SBA [3H]TPP 0.20 (low salt)
0.04 (high salt)
nd [76]
Pae-Smr-His6
b NCC SUV MV DUA [14C]MV 2426 c nd [26]
Bpe-Smr-His6
b NCC SUV SBA [14C]MV 1005 c nd [26]
Mtu-Smr-His6
b NCC SUV SBA [14C]MV 943 c nd [26]
Eco-SugE OSE SUV ITC Et 6.1±1.5 1:1 [140]
MV 24.9±5.8
Pro 7.4±0.2
OSE SDS ITC Et 3.7±0.4 1:1 [140]
MV 5.3±1.4
Pro 4.2±1.0
TPP 4.3±0.9
OSE DDM ITC Et 6.2±1.0 1:1 [140]
MV 54±16
Pro 4.5±0.7
TPP 43±12
Bsu-EbrA and Bsu-EbrB NCC DDM SBA [3H]TPP nd 1:02 [140]
List of drug and membrane mimetic abbreviations: carbon-14 labelled methyl viologen ([14C]MV), cetylpyridinium (CTP), dodecyl-β-D-maltoside (DDM), ethidium
(Et), proflavin (Pro), methyl viologen (MV), sodium dodecyl sulfate (SDS), small unilamellar vesicles (SUV), tritium labelled tetraphenylphosphonium ([3H]TPP),
and tetraphenylphosphonium (TPP).
List of purification and experimental method abbreviations: drug uptake assay (DUA), equilibrium dialysis (ED), isothermal titration calorimetry (ITC), fluorescence
(Fluoro), Ni-column chromatography (NCC), organic solvent extraction (OSE), saturation binding assay (SBA), size exclusion chromatography–high-pressure liquid
chromatography (SEC-HPLC).
a Escherichia coli EmrE with a C-terminus myc epitope and hexahistidinyl tag.
b Escherichia coli EmrE with a C-terminus myc epitope and hexahistidinyl tag.
c Km values listed in mM.
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demonstrated that the conserved Glu residue of Bsu-EbrA
(E15A) but not Bsu-EbrB (E14A) was essential for H+/TPP
binding activity suggesting that only one Glu may be essential
and/or participate in ligand binding [135].
Although H+/substrate binding occurs at E14 (according to
Eco-EmrE), other highly conserved hydrophobic residues with-
in TM1 are also essential for substrate binding. Cysteine scan-
ning mutants of numerous residues within Eco-EmrE TM1revealed that conserved residues such as A10, I11 and T18
participate with E14 in the binding pocket based on cross-
linking analysis and alkylation accessibility studies [117–119].
According to their position on the α-helix, these residues face
the same side as E14 and variant proteins at A10 in particular
have altered TPP binding and accessibility [119].
Besides E14 (E13 in Sau-Smr), site-directed mutants target-
ing the remaining charged residues within hydrophilic loop
regions of Eco-EmrE and Sau-Smr have identified their
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Replacement of charged residues K22, E24, R29, R82 and D84
in Eco-EmrE with uncharged residues results in an overall
reduction of drug transport in proteoliposomes [124] and mu-
tants with more than one charged residue replaced had further
reduced drug transport [126]. Eco-EmrE mutants K22R, E24D,
R29K, R82K, and D84E demonstrate slight reductions in drug
transport from the wild-type protein [124]. Charged residues are
also important for substrate specificity as demonstrated for Sau-
Smr mutants E24D and E80D, which conferred increased host
resistance to the dye Et only, whereas replacements to Q
resulted in loss of resistance to Et and resistance to Bz only
[22,68]. Interestingly, replacement of D24E in S. aureus QacH
did not result in any alterations to the host drug resistance
phenotype suggesting that charged residues from other SMR
homologues may lack substrate specificity or have more subtle
effects on substrate specificity [49] (refer to Supplementary
Table 1 for a list of site-directed variants of SMR proteins).
In addition to charged residues, substrate specificity of SMR
proteins has also been linked to aromatic residues. Replacement
of conserved residues Y40 and Y60 in Eco-EmrE with other
aromatic, hydrophobic or polar residues results in unique al-
terations in the host drug resistance profile relative to strains
expressing wild-type Eco-EmrE [4,117,146,147]. The remain-
ing poorly conserved tyrosine residues Y6 and Y53 in Eco-
EmrE demonstrated similar drug resistance profiles to that of
the wild-type which strongly indicated that only the conserved
aromatics play a critical role to substrate binding and specificity
of the protein [119,147] (Supplementary Table 1).
Another highly conserved aromatic residue, W63 in Eco-
EmrE and W62 in Sau-Smr, also alters the substrate specificity
and protein fidelity depending on the nature of the replaced
residue. Mutants of Eco-EmrE replacing W63 with C or Y
residues result in completely inactive protein that was incapable
of drug binding [146,148]. Eco-EmrEW63F variants resulted in
transport active protein that was capable of TPP drug binding but
demonstrated sensitivity to Et, Ac, and MV [4,148]. For SMR
homologue Sau-Smr, replacement of W62 to Q or Y resulted in
host susceptibility to Et and BZ only [22] and complete loss of
resistance to all drugs tested in Sau-Smr W62F variants [68].
It is uncertain whether residue alterations that completely
eliminate transport activity or alter substrate specificity truly
participate in the drug binding pocket of the protein. These
residues may be responsible for proper protein folding orFig. 5. A cartoon summary of the proposed drug transport mechanisms of EmrE.
oligomerized states. In all diagrams EmrE is represented as a monomer (wide cy
within the lipid bilayer (grey unfilled circles connected by two straight lines). Em
line and lipophilic cation substrate is indicated by filled grey circles with a white
arrows. Numbers indicated above EmrE complexes represent each distinct stage or
EmrE trimer transport mechanism proposed by Muth and Schuldiner [142] and
proposed by Ubarretxena-Belandia et al. [64]. (C) The proton-coupled translocatio
for each monomer are indicated as numbered cylinders (monomer 1′ and monom
[144]. (E) The drug-efflux mechanism of the EmrE tetramer proposed by Ma a
Pornillos et al. [67]. To clarify this mechanism, only gating TM α-helices A1
mechanisms of tetrameric EmrE (I) or dimeric EmrE (II) by Weinglass et al. [138
shown for clarity. (H) The binding and transport model of EmrE by Winstone et a
each EmrE monomer.structural stability as is predicted for a variety of conserved
hydrophobic residues within TM strands 1–4 (Supplementary
Table 1) of SMR proteins based on cross-link analysis of Eco-
EmrE site directed mutants [118,146]. Due to the small size of
the protein, these conserved and semi-conserved residues likely
play multiple roles that participate in substrate binding, oligo-
merization, and structural stability making it difficult to assign a
single role for any particular residue.
13. Transport mechanism models of SMR proteins
The transport mechanism of SMR proteins is an intriguing
and as yet unanswered question. Since SMP subclass proteins in
particular confer host cell resistance to a broad range of
substrates, this suggests that they possess a generic substrate
binding site. Numerous mechanisms have been proposed for the
homooligomer Eco-EmrE by various research groups and are
modeled from the available biochemical data for ligand binding,
oligomerization, and site-directed mutagenesis (Fig. 5).
The transport mechanism proposed by Muth and Schuldiner
[142] and Yerushalmi and Schuldiner [145] suggested that an
EmrE trimer is the functional oligomeric form (Fig. 5A) based
on E14 residue time-sharing experiments and site-directed mu-
tants. In this model, two of the three EmrE E14 residues de-
protonate upon the approach of a single positively charged drug
molecule (step 1). The cationic substrate binds within a hydro-
phobic pocket formed by the trimer stabilized by the negatively
charged E14 residues. A subsequent conformational change in
the protein complex opens the pocket to face the periplasmic
side of the membrane while closing off cytoplasmic pocket
exposure. Two protons from within the periplasm move into the
binding pocket catalyzing the release of the substrate into the
periplasm. Re-protonation within the binding pocket relaxes the
trimer complex back into its initial conformation regenerating
the cycle. As discussed in previous sections, EmrE trimers have
been observed on SDS-PAGE gels and have not been identified
in other stringent functional assays.
Analysis of His6-tagged Eco-EmrE by cryo-EM demonstrat-
ed its arrangement as dimers in both the presence and absence of
substrate [61,62,64]. Using information obtained from these
studies, a few mechanistic models were proposed involving an
EmrE dimer [64,149] (Fig. 5B, C). According to both models,
loss of two protons from the binding site, located between both
EmrE monomers, permits substrate within the inner lipid leafletEach panel represents a drug transport mechanism for EmrE in a variety of
linders) or as a representative TM strand from a monomer (narrow cylinder)
rE residue E14 is represented by black filled circles with a white horizontal
cross. The direction of proton and substrate movement is indicated by black
step in the mechanism. Refer to text for a discussion of each model. (A) The
Yerushalmi and Schuldiner [145]. (B) The EmrE dimer transport scheme
n of substrate mechanism proposed by Fleishman et al. [149]. TM α-helices
er 2). (D) The kinetic transport model of EmrE proposed by Soskine et al.
nd Chang [65]. (F) The proton-dependent drug translocation mechanism of
, A2 and B1 from each monomer are shown. (G) The alternate transport
]. In both models, only TM1 (narrow cylinder) from each EmrE monomer is
l. [6]. In this model, unfilled half ovals indicate the ligand binding pocket for
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alteration within the protein results in the tilt of TM helices
(TM1–3 of each monomer; Fig. 5C) approximately 20° with
respect to the in-plane axis of symmetry, exposing the substrate
to the periplasm (steps 2–3). Movement of two protons into the
newly formed pocket results in the displacement of the substrate
into the periplasm or outer leaflet of the membrane, causing a
proton-driven conformational change back to its original pro-
ton-bound arrangement (steps 4 and 1). Support for a charged
residue nestled within a hydrophobic pocket by this model has
been demonstrated by Eco-EmrE TM1 spin labeling experi-
ments that predict a V-shaped chamber central to the N-terminus
of the protein [128].
A monomeric EmrE drug transport mechanism was also
proposed based on the results from proton-substrate binding
assays of detergent solubilized EmrE by Soskine et al. [144]
(Fig. 5D). In this model, an EmrE monomer releases a single
proton prior to substrate binding to residue E14 (steps 1–2). The
bound drug is translocated from the cytoplasmic side to the
periplasmic surface where a proton binds to E14 and accelerates
substrate release (steps 3–4). During binding of either proton or
substrate the monomer can face either side of the membrane
indicating that proton/substrate competition for E14 is part of
this mechanism. Hence, substrate binding and protonation/de-
protonation could occur from either side of the membrane and
substrate/proton are just as likely to be released to the cytoplasm
(i.e., a symport-based system). This model agrees with other
drug binding studies where EmrE is capable of binding ligand
as a monomer [6,139,140] but it does not account for experi-
mental results that demonstrate transport activity upon EmrE
oligomerization [4,126,136]. Furthermore, this model raises
an interesting question concerning proton directionality in the
EmrE transport mechanism. Experimental evidence supporting
a symport-based mechanism of drug/proton transport has not
been demonstrated and most studies strongly support an anti-
port-based mechanism for SMR proteins [3,22,145,150]. How-
ever, site-directed mutagenesis of Eco-SugE residues that would
increase the overall sequence identity to an SMP protein pro-
duced mutants that were capable of importing a variety of sub-
strates [88]. Based on this experiment a symport mechanism of
substrate transport may be entirely possible for SMR proteins.
Although the X-ray diffraction of EmrE crystal structures
have been retracted [65,67,131], the proposed mechanism from
these studies should still be addressed based on their argument
for dual topology [100–103]. The drug-efflux mechanism of
tetrameric EmrE proposed by Ma and Chang [65] postulates
that substrate binding occurs between two sets of EmrE dimers
oriented oppositely from each other in the membrane (step 1)
(Fig. 5D). Protonation of E14 residues by both EmrE subunits in
the trimer not participating in substrate binding results in a
conformational tilting of one of the two EmrE dimers (steps 2–
3). This proton-driven tilt displaces the substrate from the
cytoplasmic side to face the periplasmic surface. At this point,
protons are released into the cytoplasm after shuffling from the
non-substrate participating E14 to the substrate-bound E14 in
each EmrE dimer or protons are released directly from the E14
residues that initially bound the protons (steps 3–4). Protonmovement and release catalyze the expulsion of substrate from
the binding pocket and re-orientation of the adjacent EmrE
dimer back to its original unbound tetrameric form (steps 4 and
1). This model supports experimental evidence that suggests
that EmrE monomers are arranged in dual orientation
[100–103]. Although a tetrameric arrangement of EmrE has
been structurally identified by EM and by various biophysical
techniques [62,64,137], functional activity of EmrE has only
been shown for dimers [126].
Another transport mechanism attempting to resolve the dif-
ferences observed from the EM crystal structures and X-ray
diffraction structures has also been reported. The proton-depen-
dant drug translocation mechanism of Pornillos et al. [67] pro-
posed that a fully protonated EmrE binding pocket in the dimer
interacts with the substrate according to the EM structure (step 1)
(Fig. 5F). This EmrE arrangement undergoes a conformational
alteration upon deprotonation (steps 2–3) that resolves the EmrE
dimer into the X-ray diffraction crystal structure (step 4) [65].
The validity of this mechanism is uncertain due to the retracted
X-ray diffraction structure [131].
Two transport mechanisms were proposed by Weinglass
et al. [138]. The first model accounted for a tetrameric EmrE
mechanism based on the high-resolution data and the second
model combined existing biochemical data together that
suggested a functional EmrE dimer (Fig. 5G). The first transport
mechanism is modeled from the structural evidence [65]. In this
mechanism two EmrE dimers, both with oppositely oriented
monomers facing the cytosol, interact together binding one drug
molecule to two E14 from similarly facing EmrE subunits in
each dimer (Fig. 5G, I). The remaining E14 residues from both
periplasmic facing subunits of each dimer neutralize the de-
localized charge of the substrate by binding two protons that
result in a conformational change, liberating the substrate into
the periplasm. The second mechanism involves a single EmrE
dimer that has both E14 residues for each monomer involved in
ligand binding from the cytoplasm (Fig. 5G, II). Similar to the
first mechanism above, both E14 residues release bound sub-
strate to the periplasm upon a conformational change resulting
from the protonation of both E14 residues in the dimer.
Finally, the transport mechanism proposed byWinstone et al.
[6] accounts for the variation in both oligomeric status and
ligand binding by EmrE (Fig. 5H). The model suggests that
EmrE can adopt numerous multimeric states that may be de-
pendent on the nature of the target lipophilic substrate. The
expected direct membrane partitioning of many lipophilic sub-
strates shown to have KD values for the protein in the nM to μM
range is also taken into account by this model [139]. In this
model, monomeric EmrE can bind either membrane or solvent
localized ligands which can be released into the periplasm upon
protonation as proposed by Soskine et al. [144]. Depending on
the charge of the substrate, certain ligand-bound EmrE mono-
mers may require oligomerization with another EmrE monomer
to accommodate greater charge differences. Again, in these
newly formed EmrE dimers substrate release is facilitated upon
proton binding. Alternatively, non-ligand bound EmrE dimers
may participate in drug binding and require protonation for
substrate release similar to other dimeric models proposed
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multimerize to form dimers or trimers and subsequently higher
structures such as tetrameric dimers of dimers which account for
the high-resolution structures of EmrE [61,62,64,65,67].
Further support of such a monomer to multimer mechanism is
that EmrE reconstituted in lipid extract SUV binds ligand at a
1:1 ratio with μM KD values [136]. It has been demonstrated
that EmrE reconstituted in this fashion demonstrates transport
activity [5]. Thus it binds as a monomer which leads to
transport. Taken together with other proposed transport
mechanisms, this model appears to accommodate the differ-
ences that have been observed among the biochemical and
structural EmrE data. However, it would be premature to
suggest that the monomer transports, as there may be
subsequent dimerization that was not detected by ITC under
the conditions of the experiment. Thus for the Winstone et al.
[6] model to hold elements of both models, mechanisms shown
in Fig. 5D and G must also be considered.
Attempts to explain the broad substrate specificity of all
four transporter families have led to the suggestion of other
possible transport models that lack proposed mechanisms.
Since a SMR protein relies on proton-driven transport, its
mechanism may share similarities to the reversible intramem-
branous domain association that permits transient lateral gating
similar to the inner membrane protein translocation complex
SecYEG [39]. Another proposed transport mechanism is a
substrate “flip” mechanism observed for both bacterial and
eukaryotic membrane proteins where drug binds to the channel
within the cytoplasmic facing inner lipid leaflet and gets
flipped to the outer leaflet [6,39,46,151]. Since SMR proteins
target highly lipophilic substrates for export, it is far more
likely that these compounds arrive to the proteins within the
membrane itself as demonstrated by their membrane partition-
ing ability [113,139]. A flip-based transport mechanism may
not be far-fetched since other primary and secondary “flippase”
membrane proteins are thought to involve substrate export
using a monovalent cation antiport mechanism [14] which
have some commonalities to predicted SMR mechanisms
[39,151].
Transport mechanisms for SUG and PSMR subclass proteins
have not been proposed due to the lack of sufficient experimental
data. However, if the PSMR ligand binding results of Bsu-
EbrAB is relevant to all SMR proteins, it may support a transport
mechanism that involves particular Glu residues in the asym-
metric multimeric complex [135]. Nevertheless, these proteins
likely emulate one or part of the potential SMP protein transport
models based on their high homology.
14. Concluding remarks
So what can be taken from all of the SMR protein family
studies? With respect to the structural arrangements of the SMR
proteins, the debate will likely continue until the structures
derived from higher resolution techniques reflects the biochem-
ical data and vice versa. The unfortunate circumstances that
have lead to the retraction of the EmrE X-ray diffraction
structures [131] have elicited relief and frustration felt by manytrying to unite the structural data to the biochemical data [152–
155]. This has also increased anticipation for the revised EmrE
X-ray diffraction structures based on published comments from
Dr. G. Chang himself that suggest the revised calculation
analysis makes far more biochemical sense [153], so we will
have to wait and see.
As discussed above, many research groups have posed
strong arguments in favor of a single and dual topology: perhaps
this unique protein is functional in both orientations. Determi-
nation of SMR protein membrane topology will be essential to
accurately determine the precise transport mechanism and
direction of substrate transport. Variability of the EmrE
multimeric state under different isolation and analysis condi-
tions also appears to support a transport mechanism that may
involve a number of different oligomeric stages or intermediate
conformational arrangements. Clearly, EmrE oligomers are only
weakly associated in detergent and thus perhaps even in the
membrane, which in part has confused the question of its
multimeric state. A warning to all is given by Le Maire et al.
[156] who showed that differing detergent concentrations can
lead to different solubilized multimeric forms of integral
membrane proteins. Despite a contested topology and uncertain
multimeric arrangement, these proteins can still serve as an
interesting model transporter system.
Since the phylogenetic distribution and residue conservation
of known SMR proteins demonstrates that PSMR members fall
into both the SMP and SUG groups, it is evident that PSMR
proteins should form a third unique subclass. The requirement
for two distinct PSMR proteins to confer a drug resistance
phenotype emphasizes the unique distinction of PSMR
proteins from either SUG or SMP subclasses. Furthermore,
the drug resistance profiles of SMR members from each
subclass underscore their potential to play different roles for
the cells.
Finally, these little multidrug transport proteins continue to
produce fascinating answers to structural biology questions that
focus on how such small proteins can facilitate the transport of
such a broad range of lipophilic substrates. Their petite stature
has also strongly suggested that they serve as the evolutionary
building blocks of larger multidrug transporter proteins [7,9,78,
103,129]. Hence these small proteins are likely to contribute an
enormous amount of information for future membrane protein
studies.
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